AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins

Clinical trial results Company update Drug approval AI-generated analysis

πŸ“ˆ AbbVie recently delivered Phase 3 readouts for SKYRIZI and RINVOQ in Crohn's disease alongside new FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer.

πŸ’Š Early obesity data for ABBV-295 and Phase 2 results for zumilokibart in atopic dermatitis have added to the pipeline momentum ahead of the next earnings update.

πŸ“ˆ Share price climbed to US$281.12, delivering a 9.33% one-month return and a 22.59% year-to-date gain as investors reassess growth potential.

πŸ’° Total shareholder return sits at 25.85% over one year, with performance more than doubling over three and five-year periods indicating sustained investor confidence.

πŸ”„ Management reports that Humira erosion of approximately US$18 billion has been fully offset by roughly US$28 billion of growth from newer platforms.

πŸ“… 2026 guidance is projected to be almost US$10 billion above the pre-Humira peak, reinforcing the case for revenue diversification and long-term stability.

βš–οΈ Analyst consensus fair value is pegged at US$278.61, which is nearly level with the latest close of US$281.12, leaving a narrow gap for new buyers.

πŸ“‰ The SWS DCF model estimates a fair value of US$497.77, framing the current price of US$281.12 as trading about 43.5% below estimated intrinsic value.

⚠️ Key risks to the bullish narrative include potential tightening drug price pressure and faster-than-expected competition for SKYRIZI and RINVOQ.

Bullish Signals
  • AbbVie delivered positive Phase 3 readouts for SKYRIZI and RINVOQ in Crohn's disease, reinforcing the strength of its core immunology franchises.
  • The company secured new FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, signaling regulatory confidence in its oncology pipeline.
  • Early obesity data for ABBV-295 and Phase 2 results for zumilokibart in atopic dermatitis demonstrate continued innovation across metabolic and skin disease segments.
  • Share price climbed to US$281.12 with a 9.33% one-month return and 22.59% year-to-date gain, reflecting strong market momentum.
  • Total shareholder return reached 25.85% over one year, with performance more than doubling over three and five-year periods.
  • Management reports that Humira erosion of approximately US$18 billion has been offset by roughly US$28 billion of growth from other platforms.
  • 2026 guidance is projected to be almost US$10 billion above the pre-Humira peak, validating the success of post-Humira diversification strategy.
Risk Factors
  • Key risks to the bullish narrative include potential tightening drug price pressure that could impact revenue growth from blockbuster franchises.
  • SKYRIZI and RINVOQ face faster-than-expected competition in the immunology market, which could erode market share and pricing power.
Full Analysis
AbbVie (ABBV) has recently generated significant market attention following a series of positive clinical data readouts and regulatory milestones across its immunology, oncology, and metabolic franchises. Key developments include Phase 3 results for SKYRIZI and RINVOQ in Crohn's disease, FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, early obesity data for ABBV-295, and Phase 2 results for zumilokibart in atopic dermatitis. The stock has rallied to US$281.12, reflecting a 9.33% return over the past month and a 22.59% year-to-date gain. Total shareholder return stands at 25.85% over one year, with performance more than doubling over three and five-year periods. This momentum suggests investors are reassessing the company's growth potential and pipeline risk following these updates. Valuation perspectives on AbbVie remain divergent. While analyst consensus pegs fair value near the current price of US$281.12, suggesting a slight overvaluation, an SWS DCF model estimates a fair value of US$497.77, implying the stock trades approximately 43.5% below that intrinsic value. Management reports that Humira erosion of roughly US$18 billion has been offset by US$28 billion in growth from other platforms, with 2026 guidance projected to be nearly US$10 billion above pre-Humira peaks.